IQVIA Named to FORTUNE’s 2023 List of “World’s Most Admired Companies,” Ranked #1 in Its Category for the Second Consecutive Year
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, has been named to FORTUNE magazine’s “World’s Most Admired Companies” list for the sixth consecutive year.
Once again, IQVIA earned the first-place ranking within FORTUNE’s Health Care: Pharmacy and Other Services category and ranked number one for innovation, people management, use of corporate assets, social responsibility, quality of products and services, global competitiveness and long-term investment value.
“It is an honor to be named to FORTUNE’s list of the World’s Most Admired Companies for the sixth year in a row. This distinction is a recognition of the impact our 86,000 employees have on driving healthcare forward. Their passion and expertise drive innovations that help improve patient outcomes across the world,” said IQVIA Chairman and CEO Ari Bousbib.
FORTUNE’s World's Most Admired Companies list is the definitive report card on corporate reputation. Since 1997, FORTUNE has identified, selected, and ranked the World’s Most Admired Companies, identifying the business practices that make these companies highly regarded among their peers.
Most Admired Company Survey Methodology
FORTUNE collaborated with Korn Ferry on this survey of corporate reputation. They began with a universe of about 1,500 candidates: the 1,000 largest U.S. companies ranked by revenue, along with non-U.S. companies in the Fortune Global 500 database that have revenues of $10 billion or more. The list was then winnowed to the highest-revenue companies in each industry, a total of 645 in 27 countries, and the top-rated companies were picked from that pool.
To determine the best-regarded companies in 52 industries, Korn Ferry asked executives, directors, and analysts to rate enterprises in their own industry on nine criteria, from investment value and quality of management and products to social responsibility and ability to attract talent. A company’s score must rank in the top half of its industry survey to be listed.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 86,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
Nick Childs, IQVIA Investor Relations (firstname.lastname@example.org)
Trent Brown, IQVIA Media Relations (email@example.com)